Grail Inc

GRAL

38.040USD

-0.610-1.58%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

85 / 509

Overall Ranking

219 / 4730

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Hold

Current Rating

40.500

Target Price

+14.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 126.09% year-on-year.

Undervalued

The company’s latest PE is -3.02, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.08M shares, decreasing 5.29% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 2.05M shares of this stock.

The company's current financial score is 6.06, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 31.84M, representing a year-over-year increase of 19.15%, while its net profit experienced a year-over-year increase of 51.48%.

Score

Industry at a Glance

Previous score

6.06

Change

0



Financials

2.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.16

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.07

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -2.87, which is -82.99% below the recent high of -0.49 and 72.62% above the recent low of -0.79.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/509

No Data

The company’s current earnings forecast score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Grail Inc is 40.50, with a high of 43.00 and a low of 38.00.

Score

Industry at a Glance

Previous score

6.50

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.50, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 36.81 and the support level at 30.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.28

Change

-0.42

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-10

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 83.61%, representing a quarter-over-quarter increase of 1.73%. The largest institutional shareholder is PRIMECAP Management, holding a total of 2.05M shares, representing 5.70% of shares outstanding, with 7.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Illumina Inc

4.50M

--

CRCM L.P.

3.64M

--

BlackRock Institutional Trust Company, N.A.

1.12M

-10.88%

PRIMECAP Management Company

Star Investors

2.05M

-1.34%

The Vanguard Group, Inc.

Star Investors

1.49M

+3.28%

Baker Bros. Advisors LP

1.63M

--

AQR Capital Management, LLC

1.34M

+60.96%

State Street Global Advisors (US)

1.27M

+11.55%

Arbiter Partners Capital Management, LLC

1.03M

+23.40%

Sessa Capital

1.51M

-21.38%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.16, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Grail Inc

GRAL

5.78 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

7.02 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Travere Therapeutics Inc

TVTX

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.